Taysha Gene Therapies’ (TSHA) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a report released on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $7.00 price objective on the stock.

Several other research analysts also recently issued reports on the stock. Canaccord Genuity Group lowered their price target on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. Needham & Company LLC reissued a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, August 13th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $6.38.

Taysha Gene Therapies Stock Up 2.7 %

Shares of NASDAQ TSHA opened at $2.27 on Tuesday. The company has a market cap of $465.22 million, a price-to-earnings ratio of 3.60 and a beta of 0.44. The company has a current ratio of 5.22, a quick ratio of 5.22 and a debt-to-equity ratio of 0.35. Taysha Gene Therapies has a 12 month low of $1.19 and a 12 month high of $4.32. The stock has a 50-day moving average price of $1.98 and a two-hundred day moving average price of $2.39.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. The business had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $3.62 million. During the same period in the prior year, the company earned ($0.38) EPS. As a group, analysts forecast that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds have recently made changes to their positions in the stock. StemPoint Capital LP acquired a new stake in Taysha Gene Therapies during the 1st quarter valued at approximately $3,122,000. Avoro Capital Advisors LLC raised its stake in Taysha Gene Therapies by 328.2% during the first quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock worth $53,526,000 after buying an additional 14,294,445 shares during the last quarter. Artal Group S.A. lifted its holdings in Taysha Gene Therapies by 0.7% in the first quarter. Artal Group S.A. now owns 3,687,548 shares of the company’s stock valued at $10,583,000 after buying an additional 24,444 shares during the period. Quantum Private Wealth LLC boosted its position in Taysha Gene Therapies by 4.6% during the second quarter. Quantum Private Wealth LLC now owns 730,520 shares of the company’s stock valued at $1,636,000 after acquiring an additional 32,000 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in Taysha Gene Therapies during the 2nd quarter worth about $1,018,000. 77.70% of the stock is currently owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.